These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 29340082

  • 1. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.
    Vervloessem T, Akl H, Tousseyn T, De Smedt H, Parys JB, Bultynck G.
    Oncotarget; 2017 Dec 19; 8(67):111656-111671. PubMed ID: 29340082
    [Abstract] [Full Text] [Related]

  • 2. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, Bultynck G.
    Biochim Biophys Acta; 2014 Oct 19; 1843(10):2240-52. PubMed ID: 24768714
    [Abstract] [Full Text] [Related]

  • 3. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H, La Rovere RM, Janssens A, Vandenberghe P, Parys JB, Bultynck G.
    Int J Dev Biol; 2015 Oct 19; 59(7-9):391-8. PubMed ID: 26260683
    [Abstract] [Full Text] [Related]

  • 4. Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2.
    Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G.
    Cell Death Differ; 2019 Mar 19; 26(3):531-547. PubMed ID: 29899382
    [Abstract] [Full Text] [Related]

  • 5. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca2+-dependent mPTP opening.
    Kerkhofs M, La Rovere R, Welkenhuysen K, Janssens A, Vandenberghe P, Madesh M, Parys JB, Bultynck G.
    Cell Calcium; 2021 Mar 19; 94():102333. PubMed ID: 33450506
    [Abstract] [Full Text] [Related]

  • 6. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR, Zhong F, Chang MJ, Greenberg E, Choudhary Y, Smith MR, McColl KS, Pink J, Reu FJ, Matsuyama S, Distelhorst CW.
    Oncotarget; 2015 Sep 29; 6(29):27388-402. PubMed ID: 26317541
    [Abstract] [Full Text] [Related]

  • 7. Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
    Distelhorst CW.
    Biochim Biophys Acta Mol Cell Res; 2018 Nov 29; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [Abstract] [Full Text] [Related]

  • 8. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H, Monaco G, La Rovere R, Welkenhuyzen K, Kiviluoto S, Vervliet T, Molgó J, Distelhorst CW, Missiaen L, Mikoshiba K, Parys JB, De Smedt H, Bultynck G.
    Cell Death Dis; 2013 May 16; 4(5):e632. PubMed ID: 23681227
    [Abstract] [Full Text] [Related]

  • 9. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling.
    Vervloessem T, Ivanova H, Luyten T, Parys JB, Bultynck G.
    Biochim Biophys Acta Mol Cell Res; 2017 Jun 16; 1864(6):968-976. PubMed ID: 27913204
    [Abstract] [Full Text] [Related]

  • 10. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
    Kerkhofs M, Vervloessem T, Stopa KB, Smith VM, Vogler M, Bultynck G.
    Biomolecules; 2020 Jul 21; 10(7):. PubMed ID: 32708132
    [Abstract] [Full Text] [Related]

  • 11. Extracellular and ER-stored Ca2+ contribute to BIRD-2-induced cell death in diffuse large B-cell lymphoma cells.
    Bittremieux M, La Rovere RM, Schuermans M, Luyten T, Mikoshiba K, Vangheluwe P, Parys JB, Bultynck G.
    Cell Death Discov; 2018 Jul 21; 4():101. PubMed ID: 30416758
    [Abstract] [Full Text] [Related]

  • 12. Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity.
    Shapovalov G, Ritaine A, Essonghe NC, de Ridder I, Ivanova H, Karamanou S, Economou A, Bultynck G, Skryma R, Prevarskaya N.
    Explor Target Antitumor Ther; 2022 Jul 21; 3(3):375-391. PubMed ID: 36045908
    [Abstract] [Full Text] [Related]

  • 13. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G, Vervliet T, Akl H, Bultynck G.
    Cell Mol Life Sci; 2013 Apr 21; 70(7):1171-83. PubMed ID: 22955373
    [Abstract] [Full Text] [Related]

  • 14. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
    de Ridder I, Kerkhofs M, Veettil SP, Dehaen W, Bultynck G.
    Biochim Biophys Acta Mol Cell Res; 2021 Apr 21; 1868(5):118983. PubMed ID: 33549704
    [Abstract] [Full Text] [Related]

  • 15. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
    Vervliet T, Lemmens I, Welkenhuyzen K, Tavernier J, Parys JB, Bultynck G.
    Biochem Biophys Res Commun; 2015 Jul 31; 463(3):174-9. PubMed ID: 25957473
    [Abstract] [Full Text] [Related]

  • 16. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
    Vervloessem T, Sasi BK, Xerxa E, Karamanou S, Kale J, La Rovere RM, Chakraborty S, Sneyers F, Vogler M, Economou A, Laurenti L, Andrews DW, Efremov DG, Bultynck G.
    Cell Death Dis; 2020 Sep 17; 11(9):769. PubMed ID: 32943617
    [Abstract] [Full Text] [Related]

  • 17. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.
    Bodo J, Zhao X, Durkin L, Souers AJ, Phillips DC, Smith MR, Hsi ED.
    Oncotarget; 2016 Oct 25; 7(43):70000-70010. PubMed ID: 27661108
    [Abstract] [Full Text] [Related]

  • 18. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.
    FEBS J; 2018 Jan 25; 285(1):127-145. PubMed ID: 29131545
    [Abstract] [Full Text] [Related]

  • 19. Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling.
    Vervloessem T, Kerkhofs M, La Rovere RM, Sneyers F, Parys JB, Bultynck G.
    Cell Calcium; 2018 Mar 25; 70():102-116. PubMed ID: 28705421
    [Abstract] [Full Text] [Related]

  • 20. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.
    Greenberg EF, McColl KS, Zhong F, Wildey G, Dowlati A, Distelhorst CW.
    Cell Death Dis; 2015 Dec 31; 6(12):e2034. PubMed ID: 26720343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.